We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

GenoLogics Targets Translational Medicine, Cancer Research with Partnership Strategy of End-to-End Solutions


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GenoLogics Targets Translational Medicine, Cancer Research with Partnership Strategy of End-to-End Solutions"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

GenoLogics Life Sciences Software Inc. has announced that it is developing a sophisticated network of key partners, to create end-to-end lab and scientific data management solutions, for various proteomics and genomics applications such as cancer research, biomarker discovery, and translational medicine.

Company leaders are actively selecting and pursuing partners with best-in-class, complementary products to provide end-to-end solutions to GenoLogics customers.

GenoLogics kicks off the partnership initiative by demonstrating fully integrated translational research and cancer research solutionsat the HUPO World Congress in Long Beach, California. 

Demonstrations include solutions for translational research featuring the following integrations to Proteus™: Institute of System Biology’s Trans Proteomic Pipeline (TPP), Proteome Software’s Scaffold, BSI’s PEAKS, GeneBio’s Phenyx, and CPAS from LabKey and the Fred Hutchinson Cancer Research Center (FHCRC), along with a mass spectrometry instrument integration with one of its key instrument partners. Individual demo stations will spotlight each of these integrations.  

GenoLogics is partnering with genomics and proteomics analysis companies to address the bioinformatics requirements customers are asking for, and provide an end to end solution on one open, integrated, automated and configurable platform. 

GenoLogics is also selecting partners with products that will enable the company to provide solutions that are focused around key application areas to address market demand.

James DeGreef, VP Product Management, stated, "This strategic partnering strategy dovetails well with our development strategy and Automated Informatics (AI) framework, a technology for automating bioinformatics tools into a pipeline and capturing results in a contextual database for search, comparison, reporting and analytics."

"Terabytes of data are generated in genomics and proteomics research labs, and we believe that excellent data management and contextual data integration is a key precursor to effective data mining, analysis and ultimately - discovery."

"Our customers need the functionality of a LIMS system, but they also need a broader informatics solution that integrates all their lab instruments and bioinformatics software, while storing all clinical, experimental, biological, and results data in a central repository or database to enable holistic analysis," DeGreef added.

"GenoLogics solutions offer all of this functionality while our partners provide additional software components that enable a fully integrated end-to-end solution perfectly suited to applications such as translational research, biomarker discovery and others."

GenoLogics has built an open, user configurable platform that acts as the central nervous system for laboratory automation and operations.

It integrates specialized software tools, multiple lab instruments, analysis packages, and technologies to offer researchers an integrated lab and data management solution.

GenoLogics’ solutions for proteomics and genomics research, Proteus and Geneus, are both built on this core platform.

On the open source software ( OSS ) partnering front, GenoLogics supports and integrates the Trans Proteomics Pipeline (TPP) and the Computational Portal Analysis System (CPAS).

Advertisement